|
1
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang CW, Yu JC, Hsieh YH, Yao CC, Chao
JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY, et al:
MicroRNA-30a increases tight junction protein expression to
suppress the epithelial-mesenchymal transition and metastasis by
targeting Slug in breast cancer. Oncotarget. 7:16462–16478.
2016.PubMed/NCBI
|
|
3
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: miR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang R, Yan S, Wang J, Deng F, Guo Y, Li
Y, Fan M, Song Q, Liu H, Weng Y, et al: miR-30a regulates the
proliferation, migration, and invasion of human osteosarcoma by
targeting Runx2. Tumour Biol. 37:3479–3488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li WF, Dai H, Ou Q, Zuo GQ and Liu CA:
Overexpression of microRNA-30a-5p inhibits liver cancer cell
proliferation and induces apoptosis by targeting MTDH/PTEN/AKT
pathway. Tumor Biol. 37:5885–5895. 2016. View Article : Google Scholar
|
|
6
|
Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H,
Yin R and Xi T: AEG-1 3′-untranslated region functions as a ceRNA
in inducing epithelial-mesenchymal transition of human non-small
cell lung cancer by regulating miR-30a activity. Eur J Cell Biol.
94:22–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Wang K, Han L, Zhang A, Shi Z,
Zhang K, Zhang H, Yang S, Pu P, Shen C, et al: PRDM1 is directly
targeted by miR-30a-5p and modulates the Wnt/β-catenin pathway in a
Dkk1-dependent manner during glioma growth. Cancer Lett.
331:211–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sestito R, Cianfrocca R, Rosanò L, Tocci
P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A,
Blandino G, et al: miR-30a inhibits endothelin A receptor and
chemoresistance in ovarian carcinoma. Oncotarget. 7:4009–4023.
2016.PubMed/NCBI
|
|
9
|
Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi
TP, Zhang Y, Gao Y, Fan Y, Ni D, et al: Down-regulated miR-30a in
clear cell renal cell carcinoma correlated with tumor hematogenous
metastasis by targeting angiogenesis-specific DLL4. PLoS One.
8:e672942013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou Z, Ni M, Zhang J, Chen Y, Ma H, Qian
S, Tang L, Tang J, Yao H, Zhao C, et al: miR-30a can inhibit DNA
replication by targeting RPA1 thus slowing cancer cell
proliferation. Biochem J. 473:2131–2139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Y, Cao L, Yang L, Kang R, Lotze M and
Tang D: microRNA 30A promotes autophagy in response to cancer
therapy. Autophagy. 8:853–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ouzounova M, Vuong T, Ancey PB, Ferrand M,
Durand G, Le-Calvez Kelm F, Croce C, Matar C, Herceg Z and
Hernandez-Vargas H: MicroRNA miR-30 family regulates non-attachment
growth of breast cancer cells. BMC Genomics. 14:1392013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015.PubMed/NCBI
|
|
14
|
Xie K, Wang C, Qin N, Yang J, Zhu M, Dai
J, Jin G, Shen H, Ma H and Hu Z: Genetic variants in regulatory
regions of microRNAs are associated with lung cancer risk.
Oncotarget. 7:47966–47974. 2016.PubMed/NCBI
|
|
15
|
Tang R, Liang L, Luo D, Feng Z, Huang Q,
He R, Gan T, Yang L and Chen G: Downregulation of miR-30a is
associated with poor prognosis in lung cancer. Med Sci Monit.
21:2514–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran
P, Sun L, Huang Q, Xie F, Du J, et al: Overexpression of miR-30a in
lung adenocarcinoma A549 cell line inhibits migration and invasion
via targeting EYA2. Acta Biochim Biophys Sin (Shanghai).
48:220–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metheetrairut C and Slack FJ: MicroRNAs in
the ionizing radiation response and in radiotherapy. Curr Opin
Genet Dev. 23:12–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, Lu X and Cao Y: MicroRNA and
signal transduction pathways in tumor radiation response. Cell
Signal. 25:1625–1634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao L, Bode AM, Cao Y and Dong Z:
Regulatory mechanisms and clinical perspectives of miRNA in tumor
radiosensitivity. Carcinogenesis. 33:2220–2227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Zheng L, Huang J, Gao F, Lin X,
He L, Li D, Li Z, Ding Y and Chen L: miR-124 radiosensitizes human
colorectal cancer cells by targeting PRRX1. PLoS One. 9:e939172014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu
J, Xue J, Liu T, Liang Y and Wu G: miR-200c increases the
radiosensitivity of non-small-cell lung cancer cell line A549 by
targeting VEGF-VEGFR2 pathway. PLoS One. 8:e783442013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang Z, Ahn J, Guo D, Votaw JR and Shim
H: MicroRNA-302 replacement therapy sensitizes breast cancer cells
to ionizing radiation. Pharm Res. 30:1008–1016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee YY, Yang YP, Huang MC, Wang ML, Yen
SH, Huang PI, Chen YW, Chiou SH, Lan YT, Ma HI, et al:
MicroRNA142-3p promotes tumor-initiating and radioresistant
properties in malignant pediatric brain tumors. Cell Transplant.
23:669–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu CG, Yang MF, Fan JX and Wang W: miR-30a
and miR-205 are downregulated in hypoxia and modulate
radiosensitivity of prostate cancer cells by inhibiting autophagy
via TP53INP1. Eur Rev Med Pharmacol Sci. 20:1501–1508.
2016.PubMed/NCBI
|
|
25
|
Shanware NP, Zhan L, Hutchinson JA, Kim
SH, Williams LM and Tibbetts RS: Conserved and distinct modes of
CREB/ATF transcription factor regulation by PP2A/B56gamma and
genotoxic stress. PLoS One. 5:e121732010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khoronenkova SV and Dianov GL: ATM
prevents DSB formation by coordinating SSB repair and cell cycle
progression. Proc Natl Acad Sci USA. 112:3997–4002. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou WC, Hu LY, Hsiung CN and Shen CY:
Initiation of the ATM-Chk2 DNA damage response through the base
excision repair pathway. Carcinogenesis. 36:832–840. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rondeau S, Vacher S, De Koning L, Briaux
A, Schnitzler A, Chemlali W, Callens C, Lidereau R and Bièche I:
ATM has a major role in the double-strand break repair pathway
dysregulation in sporadic breast carcinomas and is an independent
prognostic marker at both mRNA and protein levels. Br J Cancer.
112:1059–1066. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neumann J, Yang Y, Köhler R, Giaisi M,
Witzens-Harig M, Liu D, Krammer PH, Lin W and Li-Weber M: Mangrove
dolabrane-type of diterpenes tagalsins suppresses tumor growth via
ROS-mediated apoptosis and ATM/ATR-Chk1/Chk2-regulated cell cycle
arrest. Int J Cancer. 137:2739–2748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang H, Reinhardt HC, Bartkova J,
Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and
Hemann MT: The combined status of ATM and p53 link tumor
development with therapeutic response. Genes Dev. 23:1895–1909.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng YC, Xing R, Zeng J, Xue M, Chi F, Xin
Y, Fan GL, Wang HM, Duan QY, Sun YN, et al: Sodium glycididazole
enhances the radiosensitivity of laryngeal cancer cells through
downregulation of ATM signaling pathway. Tumour Biol. 37:5869–5878.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gudkov AV and Komarova EA: The role of p53
in determining sensitivity to radiotherapy. Nat Rev Cancer.
3:117–129. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bruno T, De Nicola F, Iezzi S, Lecis D,
D'Angelo C, Di Padova M, Corbi N, Dimiziani L, Zannini L, Jekimovs
C, et al: Che-1 phosphorylation by ATM/ATR and Chk2 kinases
activates p53 transcription and the G2/M checkpoint. Cancer Cell.
10:473–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berindan-Neagoe I, Monroig PC, Pasculli B
and Calin GA: MicroRNAome genome: a treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
